Profile
Sector:
HealthcareCountry:
CanadaIPO:
15 January 2019Website:
http://www.cardiolrx.comNext earnings report:
14 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Mon, 26 Aug 2024 22:34:45 GMTDividend
Analysts recommendations
Institutional Ownership
CRDL Latest News
Cardiol Therapeutics (NASDAQ: CRDL) recently released its first quarter 2024 results, showing earnings per share of -10 cents.
Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) presented encouraging advancements in its Phase II clinical trial, ARCHER, at the World Congress on Acute Heart Failure 2024. The conference offered an opportunity for Univ. to showcase their research.
Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) said it had made significant strides in 2023 and early 2024 to advance its offerings of novel therapeutic solutions to patients with underserved heart diseases. In an operational update looking at the 2023 calendar year, CEO David Elsley highlighted some of the main milestones the company achieved.
Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) said it had made significant strides in 2023 and early 2024 to advance its offerings of novel therapeutic solutions to patients with underserved heart diseases. In an operational update looking at the 2023 calendar year, CEO David Elsley highlighted some of the main milestones the company achieved.
Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) has reached a significant milestone in its mission to combat heart disease. The company has wrapped up patient enrollment for its Phase II open-label pilot study, known as MAvERIC-Pilot, which focuses on patients suffering from recurrent pericarditis.
Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) made headlines earlier in the week when it revealed that the US Food and Drug Administration had granted its lead drug candidate CardiolRx orphan drug designation, indicating potential efficacy in treating recurrent pericarditis. The designation provides benefits such as marketing exclusivity and fee reduction, and the company's share prices have surged as a result.
Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL), the pharmaceutical company, has been awarded Orphan Drug Designation for its lead drug candidate. The US Food and Drug Administration (FDA) awarded Cardiol the orphan status for the drug due to its potential use in helping treat both one-time and recurrent pericarditis, the inflammation of the lining around the heart.
Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) told investors it has exceeded 50% patient enrollment for its Phase II ARCHER trial. The multi-center, international, double-blind, randomized, placebo-controlled trial is investigating the safety, tolerability, and impact of CardiolRx on myocardial recovery in patients presenting with acute myocarditis.
Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) has added Massachusetts General to the enrollment process for the MAvERIC-Pilot, a Phase II open-label pilot study of lead candidate CardiolRx in patients suffering from recurrent pericarditis. The renowned Mass General, recognized for its top-notch medical research programs, joins eight other leading medical research centers in the United States dedicated to pericarditis care.
Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) announced that study results have demonstrated an experimental model of pericarditis induces mesothelial to mesenchymal transition (MMT) and that this process is inhibited by cannabidiol treatment, the active pharmaceutical ingredient in its lead candidate, CardiolRx. The study results were presented at the 2023 Annual Meeting of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases (MPD2023), held on November 15 and 16, 2023, in Belgrade, Serbia.
What type of business is Cardiol Therapeutics?
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.
What sector is Cardiol Therapeutics in?
Cardiol Therapeutics is in the Healthcare sector
What industry is Cardiol Therapeutics in?
Cardiol Therapeutics is in the Drug Manufacturers - Specialty & Generic industry
What country is Cardiol Therapeutics from?
Cardiol Therapeutics is headquartered in Canada
When did Cardiol Therapeutics go public?
Cardiol Therapeutics initial public offering (IPO) was on 15 January 2019
What is Cardiol Therapeutics website?
https://www.cardiolrx.com
Is Cardiol Therapeutics in the S&P 500?
No, Cardiol Therapeutics is not included in the S&P 500 index
Is Cardiol Therapeutics in the NASDAQ 100?
No, Cardiol Therapeutics is not included in the NASDAQ 100 index
Is Cardiol Therapeutics in the Dow Jones?
No, Cardiol Therapeutics is not included in the Dow Jones index
When was Cardiol Therapeutics the previous earnings report?
No data
When does Cardiol Therapeutics earnings report?
The next expected earnings date for Cardiol Therapeutics is 14 November 2024